Due to the rising frequency of ocular problems among the geriatric population, the market for treatments for blepharitis is anticipated to have significant expansion. Blepharitis typically affects adults over the age of 50, per a 2014 poll by the American Academy of Ophthalmology.. The market is anticipated to experience significant expansion as a result of the growing number of medications in development. For instance, phase 3 clinical trials are ongoing for the medication ISV-305, which is sponsored by InSite Vision. Patients who have blepharitis' early symptoms are treated with ISV-305. Additionally, the use of tactics like new product launches and mergers and acquisitions is anticipated to support market expansion. For instance, the Franklin-based startup Rysurg introduced BlephEx in 2015. It is the first device-based method for maintaining hygiene and cleaning eyelashes. Around 50% of ophthalmic patients experience blepharitis and dry eye symptoms, according to a 2015 research by the American Academy of Ophthalmology.
According to Coherent Market Insights, The size of the Global Blepharitis Market is anticipated to increase over the projected period at a CAGR of 4.4%, reaching $ 9.2 billion in 2030 from 2018.
Top Companies in the Blepharitis Treatment Industry:
1. Scope Ophthalmic Ltd.
The firm was founded in 2009 and has its main office in United Kingdom. Scope provides cutting-edge management products for age-related macular degeneration and ocular surface disease in addition to a reputable line of nutritional supplements. A forward-thinking business that sells goods for eye care
2. NovaBay Pharmaceuticals Inc.
The company was started in 2000 and is based in California, United States. As a biopharmaceutical business, NovaBay Pharmaceuticals Inc. focuses on product development and commercialization for the topical anti-infective markets. The debut of 15% Niacinamide Pore Minimising Serum, the newest product in the DERMAdoctor® Picture Porefect® series, was announced by the firm in October 2022.
3. Thea Pharmaceuticals Ltd.
The firm was started in 2008 and has its headquarters in United Kingdom. The business specialises in the development, research, and marketing of products for eye care. The business announced in January 2022 that it has reached a deal to buy seven branded ophthalmic products from Akorn Operating business LLC. Thea Pharma announced in December 2022 that IYUZEHTM has received FDA approval for lowering elevated intraocular pressure (IOP) in patients with open-angle glaucoma or ocular hypertension.
4. Perrigo Laboratories
The company was established in 1887 and is based in Dublin, Ireland. Perrigo buys, makes, and sells generic prescription medications, active pharmaceutical components, and consumer healthcare products (for repricing). The business disclosed in February 2020 that it has struck an agreement to pay $113 million for the oral care assets of High Ridge Brands.
5. InSite Vision Incorporated
The business was started in 1986 and has its main office in California, United States. Based on its DuraSite drug delivery technology, nSite Vision Incorporated creates ophthalmic pharmaceutical solutions. The company also creates glaucoma diagnostic and prognostic technologies with a genetic basis.
6. Novartis AG
The company was started in March 1996 and has locations in Cambridge, Massachusetts and Basel, Switzerland. Novartis provides coverage for all types of medications, including prescription, over-the-counter, immunisations, diagnostics, eyewear, and veterinary care. Through its firms, Novartis engages in a number of direct activities, including handling, marketing, operations, and research.
7. Merck & Co.
The company was founded in 1891 and is located in New Jersey, United States. Pharmaceuticals, vaccines, biologic therapies, and goods for animal health are all produced by Merck. Merck announced in April 2023 that it will pay $10.8 billion to purchase Prometheus Biosciences Inc. The business declared in September 2022 that it would purchase Vence, a firm that manages cattle, for an unknown fee and incorporate it into Merck Animal Health.
*Definition: Chronic inflammation of the eyelids is brought on by blepharitis. When tiny oil glands close to this area become blocked, blepharitis, which often affects the area of the eyelid where eyelashes grow, results in irritation and redness of the eyes.
